Strs Ohio Has $977,000 Position in Genomic Health, Inc. (NASDAQ:GHDX)

Share on StockTwits

Strs Ohio raised its holdings in Genomic Health, Inc. (NASDAQ:GHDX) by 30.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,800 shares of the medical research company’s stock after buying an additional 3,900 shares during the period. Strs Ohio’s holdings in Genomic Health were worth $977,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Northwestern Mutual Wealth Management Co. increased its stake in Genomic Health by 166.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after buying an additional 493 shares during the last quarter. Quantamental Technologies LLC increased its stake in Genomic Health by 19.1% in the 1st quarter. Quantamental Technologies LLC now owns 3,332 shares of the medical research company’s stock valued at $233,000 after buying an additional 534 shares during the last quarter. Manchester Capital Management LLC acquired a new stake in Genomic Health in the 1st quarter valued at $56,000. Rhumbline Advisers increased its stake in Genomic Health by 3.0% in the 1st quarter. Rhumbline Advisers now owns 30,602 shares of the medical research company’s stock valued at $2,144,000 after buying an additional 895 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in Genomic Health by 1.3% in the 1st quarter. Nordea Investment Management AB now owns 72,456 shares of the medical research company’s stock valued at $5,077,000 after buying an additional 946 shares during the last quarter. Hedge funds and other institutional investors own 95.63% of the company’s stock.

A number of research analysts have recently commented on GHDX shares. Canaccord Genuity downgraded shares of Genomic Health from a “buy” rating to a “hold” rating and decreased their price objective for the company from $77.00 to $72.00 in a research report on Tuesday, July 30th. Needham & Company LLC downgraded shares of Genomic Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 30th. JPMorgan Chase & Co. raised shares of Genomic Health from an “underweight” rating to a “neutral” rating and lifted their price objective for the company from $60.00 to $72.00 in a research report on Monday, July 29th. Deutsche Bank decreased their price objective on shares of Genomic Health from $80.00 to $55.00 and set a “hold” rating for the company in a research report on Thursday, May 30th. Finally, Barclays raised shares of Genomic Health from an “underweight” rating to an “equal weight” rating and lifted their price objective for the company from $45.00 to $72.00 in a research report on Tuesday, July 30th. Nine investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $69.86.

Shares of GHDX opened at $74.90 on Wednesday. The company has a 50-day moving average price of $63.20. Genomic Health, Inc. has a one year low of $50.77 and a one year high of $92.18. The company has a market cap of $2.74 billion, a P/E ratio of 71.33 and a beta of 1.06. The company has a current ratio of 5.74, a quick ratio of 5.74 and a debt-to-equity ratio of 0.17.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Monday, July 29th. The medical research company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.07. Genomic Health had a net margin of 11.69% and a return on equity of 19.51%. The company had revenue of $114.14 million during the quarter, compared to the consensus estimate of $110.78 million. During the same quarter last year, the firm posted $0.23 EPS. The company’s quarterly revenue was up 19.4% on a year-over-year basis. As a group, analysts expect that Genomic Health, Inc. will post 1.5 earnings per share for the current year.

In related news, insider Steven Shak sold 50,000 shares of Genomic Health stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $51.38, for a total transaction of $2,569,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James J. Vaughn sold 8,745 shares of Genomic Health stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $52.47, for a total transaction of $458,850.15. The disclosure for this sale can be found here. Insiders have sold a total of 290,601 shares of company stock valued at $18,833,446 in the last ninety days. 31.30% of the stock is currently owned by insiders.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Lowers Stake in Sandy Spring Bancorp Inc.
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Buys New Position in Radian Group Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Has $7.26 Million Position in Rhinebeck Bancorp Inc
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Buys Shares of 402,288 Mainstreet Bank Common Stock
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
EJF Capital LLC Grows Stock Position in First Savings Financial Group Inc
SB Financial Group Inc  Shares Bought by EJF Capital LLC
SB Financial Group Inc Shares Bought by EJF Capital LLC


© 2006-2019 Ticker Report